Viewing Study NCT04494503

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:23 PM
Ignite Modification Date: 2026-02-22 @ 9:36 AM
Study NCT ID: NCT04494503
Status: RECRUITING
Last Update Posted: 2025-04-16
First Post: 2020-07-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Sponsor: Ascentage Pharma Group Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
None Small Lymphocytic Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None APG-2575 View
None rituximab View
None ibrutinib View
None chronic lymphocytic leukemia(CLL) View
None small lymphocytic lymphoma(SLL) View